Neuren Pharmaceuticals Updates on Share Buy-Back Program

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.

Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program, with a total of 3,939,424 securities bought back before the previous day and an additional 60,082 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, reflecting confidence in its business prospects and commitment to returning capital to shareholders.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work in creating treatments for conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in the market.

Average Trading Volume: 722,917

Technical Sentiment Signal: Buy

Current Market Cap: A$1.77B

Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.